Patent classifications
G01N31/00
Cumulative differential chemical assay identification
An apparatus comprising: a value receiver, configured to receive fluorescence values measured during a chemical reaction involving a test sample, each value pertaining to a respective physical parameter value, a difference calculator, configured to calculate differences, each difference being between respective one of the measured fluorescence values and one of reference fluorescence values of a reference sample, each reference fluorescence value pertaining to a respective physical parameter value, a cumulative index calculator, configured to calculate a cumulative index, by selecting a first difference among the calculated differences, and selecting and adding to the first difference differences, each one of the added differences being selected according to a proximity standard applied on each two differences selected in a sequence, the proximity standard being based on proximity of physical parameter values and difference size, and a similarity determiner, configured to determine similarity between the samples, using the calculated cumulative index.
In situ heat induced antigen recovery and staining apparatus and method
An automated microscope slide staining system and staining apparatus and method that features a plurality of individually operable miniaturized pressurizable reaction compartments or a pressurizable common chamber for individually and independently processing a plurality of microscope slides. The apparatus preferably features independently movable slide support elements each having an individually operable heating element.
MRI-based fat double bond mapping
Techniques, apparatus and systems are described for using parameters including chain length, number of double bonds and number of double-double bonds of a complex, magnetic resonance imaging (MRI)-generated fat spectrum to determine the composition and properties of fat and to perform various diagnostic functions. In one aspect, a method using MRI to characterize fat includes acquiring a magnetic resonance (MR) image that includes MR data from a target, determining fat characterization parameters based on the acquired MR data, and using the determined fat characterization parameters to produce a relationship between regions of fat and/or water in the MR image.
Methods to detect, treat and prevent acute cellular rejection in kidney allografts
Methods for prevention and treatment of kidney transplant rejection are described that involve determination, analysis and computation of a 3-gene molecular signature of levels of specific RNAs (IP-10 mRNA, CD3ε mRNA, and 18S rRNA) in urinary sample cells. The methods and devices described herein are diagnostic and prognostic of acute cellular rejection in kidney allografts.
Stratification of patients for assessing the suitability of a therapy
A method for stratification of a patient for assessing suitability of a therapy for the patient suffering from an ER (estrogen receptor) and/or PR (progesterone receptor) positive and HER2 (human epidermal growth factor receptor 2) negative cancer, the therapy being directed towards a signaling pathway, includes: (i) determining an activation status of an ER and/or PR signaling pathway by applying a Proximity Ligation Assay to detect in a tissue sample of the patient a presence of at least one member of the ER family, the at least one member being part of a transcription factor complex, and at least one protein selected from a group consisting of TAFs (TATA-binding protein associated factor), TBP (TATA-box binding protein), POLII (RNA polymerase II), TFII (transcription factor H), p300, CREB (cyclic-AMP response element-binding protein), and CBP (CREB binding protein), wherein the at least one protein is part of the same transcription factor complex.
CONTROL OF N-(PHOSPHONOMETHYL)IMINODIACETIC ACID CONVERSION MANUFACTURE OF GLYPHOSATE
This invention relates to the preparation of N-(phosphonomethyl)glycine (“glyphosate”) from N-(phosphonomethyl)iminodiacetic acid (“PMIDA”), and more particularly to methods for control of the conversion of PMIDA, for the identification of reaction end points relating to PMIDA conversion and the preparation of glyphosate products having controlled PMIDA content.
CONTROL OF N-(PHOSPHONOMETHYL)IMINODIACETIC ACID CONVERSION MANUFACTURE OF GLYPHOSATE
This invention relates to the preparation of N-(phosphonomethyl)glycine (“glyphosate”) from N-(phosphonomethyl)iminodiacetic acid (“PMIDA”), and more particularly to methods for control of the conversion of PMIDA, for the identification of reaction end points relating to PMIDA conversion and the preparation of glyphosate products having controlled PMIDA content.
Method for discriminating red blood cells from white blood cells by using forward scattering from a laser in an automated hematology analyzer
A method for identifying, analyzing, and quantifying the cellular components of whole blood by means of an automated hematology analyzer and the detection of the light scattered, absorbed, and fluorescently emitted by each cell. More particularly, the aforementioned method involves identifying, analyzing, and quantifying the cellular components of whole blood by means of a light source having a wavelength ranging from about 400 nm to about 450 nm and multiple in-flow optical measurements and staining without the need for lysing red blood cells.
Methods and systems for measuring anions
Embodiments of the present disclosure provide for methods for detecting the presence and/or concentration of anions in a solution, systems for detecting the presence and/or concentration of anions in a solution, anion sensor systems, and the like.
Amyloid beta detection by mass spectrometry
Provided are methods for the detection or quantitation of amyloid beta. In a particular aspect, provided herein are methods for detecting amyloid beta or fragments thereof by mass spectrometry. In another aspect, provided herein are methods for determining the ratio of amyloid beta 42 (Aβ42) to amyloid beta 40 (Aβ40). In another aspect, provided herein are methods for diagnosis or prognosis of Alzheimer's disease or dementia.